Login / Signup

Lung Screen Uptake Trial: results from a single lung cancer screening round.

Mamta RuparelSamantha L QuaifeJennifer L DicksonCarolyn HorstSophie TisiHelen HallMagali TaylorAsia AhmedPenny ShawStephen BurkeMay-Jan SooArjun NairAnand DevarajKaren SennettStephen W DuffyNeal NavaniAngshu BhowmikDavid R BaldwinSamuel M Janes
Published in: Thorax (2020)
The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based 'real-world' LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a 'lung health check'. 768/996 (77.1%) in the present analysis underwent a low-dose CT scan. 92 (11.9%) and 33 (4.3%) participants had indeterminate pulmonary nodules requiring 3-month and 12-month surveillance, respectively; 36 lung cancers (4.7%) were diagnosed (median follow-up: 1044 days). 72.2% of lung cancers were stage I/II and 79.4% of non-small cell lung cancer had curative-intent treatment.
Keyphrases
  • low dose
  • public health
  • computed tomography
  • clinical trial
  • study protocol
  • high throughput
  • phase iii
  • phase ii
  • magnetic resonance imaging
  • physical activity
  • high dose
  • rectal cancer
  • open label
  • dual energy
  • drug induced